New treatments for osteoarthritis

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 310-316

  Smelter, Elizabeth ^a   Hochberg, Marc C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

biologic agents; duloxetine; intra articular therapy; osteoarthritis

Indexed keywords

ADALIMUMAB; BOTULINUM TOXIN A; DULOXETINE; FIBROBLAST GROWTH FACTOR 18; GEVOKIZUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR ANTIBODY; OSTEOGENIC PROTEIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STRONTIUM RANELATE; TANEZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

APPETITE DISORDER; BIOLOGICAL THERAPY; BONE NECROSIS; CONSTIPATION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAND OSTEOARTHRITIS; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; MEDICATION THERAPY MANAGEMENT; MESENCHYMAL STEM CELL; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL; THROMBOCYTE RICH PLASMA; XEROSTOMIA;

BIOLOGICAL AGENTS; HUMANS; INJECTIONS, INTRA-ARTICULAR; MESENCHYMAL STEM CELL TRANSPLANTATION; OSTEOARTHRITIS, KNEE; PLATELET-RICH PLASMA; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875903570     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835f69b4     Document Type: Review

References (42)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008; 58:26-35.
2. Hoogenboom TJ, den Broeder AA, de Bie RA, Van den Ende CH. Longitudinal impact of joint pain comorbidity on quality of life and activity levels in knee osteoarthritis: data from the osteoarthritis initiative. Rheumatology (Oxford). [Epub ahead of print]
3. Losina E, Walensky RP, Reichmann WM, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011; 154:217-226.
4. Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee osteoarthritis: population based cohort study. BMJ 2011; 342:d1165.
5. Lane N, Brandt K, Hawker G, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cart 2011; 19:478-482.
6. Hochberg MC, Altman RD, April KT, et al. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64:465-474.
7. Chappel AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, int the treatment of patients with osteoarthritis knee pain: a 13-week randomized, placebo-controlled trial. Pain 2009; 146:253-260.
8. Chappel AS, Desaish D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Practice 2011; 11:33-41.
9. Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011; 27:2361-2372.
10. Hochberg MC, Wohlreich M, Gaynor P, et al. Clinically releVant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012; 39:352-358.
11. Arend WP, Malyak M, Cuthbridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55.
12. Caron JP, Fermandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39:1535-1544.
13. Chevalier X, GIraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin-1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32:1317-2132.
14. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum 2009; 61:344-352.
15. Yang KG, Raijmakers NJH, Van Arkel ERA, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a randomized controlled trial. Osteoarthritis Cart 2008; 16:498-505.
16. Magnano M, Chakravarty EF, Broudy C, et al. Pilot study of TNF inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007; 34:1323-1327.
17. Verburggen G, Wittoek R, Cruyssen BV, Elevaut D. Tumor necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomized trial on structure modification. Ann Rheum Dis 2012; 71:891-898.
18. Chevalier X, Ravaud P, Emmanuel M, et al. A randomized, multicenter, double blind, placebo-controlled trial of anti TNF alpha (adalimumab) in refractory hand osteoarthritis: The Dora Study. [abstract 2472] American College of Rheumatology 2012 Annual Meeting Abstract Supplement.
19. Lane NE, Schnitzer TJ, Birbara C, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. NEJM 2010; 363:1521-1531.
20. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritis knee pain. Osteoarthritis Cart 2011; 19:639-646.
21. Nagashima H, Suzuki M, Araki S, et al. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cart 2011; 19:1405-1412.
22. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012; 13:790-798.
23. Tanezumab Arthritis Advisory Committee Briefing Document. 2/8/2012. [Accessed on 12 November 2012].
24. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008; 67:335-339.
25. Herrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001; 16:299-308.
26. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Ann Rheum Dis 2012. [Epub ahead of print]
27. Badlani N, Oshima Y, Healy R, et al. Use of bone morphogenic protein-7 as a treatment for osteoarthritis. Clin Orthop Rela Res 2009; 467:3221-3229.
28. Hunter JH, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskel Dis 2010; 11:232-240.
29. Beyer C, Schett G. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010; 24:489-496.
30. Mahowald M, Singh J, Kushnaryov A, et al. Interim report of a randomized double blind controlled trial of intra-articular botulinum toxin type A (IA-BoNT/A) vs placebo for moderate and severe refractory knee pain due to osteoarthritis. American College of Rheumatology 2006 Annual Meeting Abstract Supplement.
31. Boon AJ, Smith J, Dahm D, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PMR 2010; 2:268-276.
32. Singh J. Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Ther Adv Musculoskelet Dis 2010; 2:105-118.
33. Sanchez M, Anitua E, Orive G, et al. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 2009; 39:345-354.
34. Leitner GC, Gruber R, Neumü ller J, et al. Platelet content and growth factor release in platelet rich plasma: a comparison of four different systems. Vox Sanguinis 2006; 91:135-139.
35. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010; 18:472-479.
36. Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011; 19:528-535.
37. Sampson S, Reed M, Silvers H, et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010; 89:961-969.
38. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy 2011; 27:1490-1501.
39. Spackova T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys med Rehabil 2012; 91:411-417.
40. Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis: preliminary report of four patients. Int J Rheum Dis 2011; 14:211-215.
41. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med 2012; 15:422-428.
42. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. [Epub ahead of print]